Question special
Lead Moderator

Thanks to everyone who is participating in this NEJM forum! I think it would be great for all our participants, readers and general well-wishers to begin by getting a sense of the needs assessment for idarucizumab.

In the paper, approximately 90/300 of the patients in the trial ended up having a bleeding event (cerebral, GI or otherwise). Does this number reflect the number of these exacerbations in the community? Are there certain patient populations that are at higher risk than others? Lastly, before idarucizumab, what was the morbidity and mortality linked to these bleeding episodes?